化学免疫疗法
医学
慢性淋巴细胞白血病
免疫学
淋巴瘤
疾病
肿瘤科
免疫疗法
移植
伊布替尼
嵌合抗原受体
干细胞
白血病
抗体
抗原
血液学
侵袭性淋巴瘤
内科学
自体干细胞移植
T细胞
治疗方法
蕈样真菌病
移植物抗宿主病
滤泡性淋巴瘤
单克隆抗体
癌症
布鲁顿酪氨酸激酶
阿勒姆图祖马
造血干细胞移植
免疫系统
临床试验
作者
Jian Li,Mark R. Dowling,Constantine Si Lun Tam,Mary Ann Anderson,Philip A. Thompson
标识
DOI:10.1182/bloodadvances.2026020197
摘要
Richter transformation (RT) is an aggressive lymphoma that arises in patients with chronic lymphocytic leukemia (CLL), most commonly diffuse large B-cell lymphoma (DLBCL-RT). Outcomes remain poor with conventional chemoimmunotherapy, reflecting the role of increased genomic instability and impaired DNA repair in the pathogenesis of RT.. Targeted therapies used in CLL (BTK or BCL2 inhibition) have shown efficacy in RT; however, durable disease control remains elusive, highlighting the need for immunological approaches. This review discusses the clinical evidence supporting immunologic approaches in RT, focusing on allogeneic stem cell transplantation, chimeric antigen T-cell (CAR T-cell) therapy, bispecific T-cell directing antibodies, and checkpoint inhibition. Allogeneic stem cell transplantation can provide long-term remission in selected patients; however, there are considerable barriers, such as the requirement for adequate patient fitness and pre-transplant disease control. Post-approval observational studies have provided evidence of the efficacy and safety of CAR T-cell therapy, as well as the risk of immunologic toxicity. Early phase studies on bispecific antibodies and checkpoint inhibition have demonstrated disease activity, and multiple studies on combination strategies are ongoing. Future priorities include optimizing disease control prior to immunologic therapy, testing novel combination approaches and conducting correlative studies to optimize future therapeutic strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI